PTPN2‐deficient CAR T cells markedly suppressed tumour growth, even when the tumours were allowed to grow to one quarter (50 mm2) of the maximal ethically permissible mammary tumour burden prior to CAR T‐cell therapy (Fig 4F). This evidence concerns the gene PTPN2 and breast cancer.